XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.4

License Agreements - Merus (Details) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended			61 Months Ended
	Jan. 31, 2022 program	Jan. 31, 2021 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) program	Dec. 31, 2016 shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2017 USD ($) $ / shares
License agreements
Purchase price of common stock							$ 150,000
Per share price (in dollars per share) | $ / shares							$ 41.33
Unrealized gain (loss) on long term investments					$ (87,590)	$ (24,072)	$ 10,426
Merus
License agreements
Fair market value of our long term investments					$ 54,900	112,900		$ 112,900
Ownership percentage					8.00%
Unrealized gain (loss) on long term investments					$ (58,000)	$ 48,100	$ 11,000
IPO | Merus
License agreements
Per share price (in dollars per share) | $ / shares		$ 24.75
Common shares purchased (in shares) | shares		350,000
Number of shares in underwritten public offering (in shares) | shares		4,848,485
Value of shares acquired		$ 8,700
Merus
License agreements
Number of independent programs | program			10
Number of additional preclinical discovery programs | program	10
Number of programs under the resulting products are co-funded for development | program	2
Associated future global development costs , if elected to co-develop	35.00%
Number of projects with participation rights | program	1
Milestone payment made under license agreement								$ 3,000
Number of programs terminated, reversal of royalties | program	1
Merus | United States
License agreements
Profit sharing			50.00%
Percentage of profit (losses)			50.00%
Merus | Minimum
License agreements
Royalty payments on future global net sales			6.00%
Merus | Minimum | United States
License agreements
Royalty payments on future global net sales			6.00%
Merus | Maximum
License agreements
Royalty payments on future global net sales			10.00%
Percentage of reverse royalty			4.00%
Merus | Maximum | United States
License agreements
Royalty payments on future global net sales			10.00%
Percentage of additional royalties			4.00%
Merus | Maximum | Development and Regulatory Milestones
License agreements
Additional milestone payments under the license agreement			$ 100,000
Merus | Maximum | Commercialization Milestones
License agreements
Additional milestone payments under the license agreement			$ 250,000
Stock purchase agreement | Merus
License agreements
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares				3,200,000
Purchase price of common stock									$ 80,000
Per share price (in dollars per share) | $ / shares									$ 25.00

X

- Definition

Represents the percentage of profits and losses shared under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	incy_CollaborationAgreementProfitSharingPercentage
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting.

+ References

No definition available.

+ Details

Name:	incy_EquityMethodInvestmentSharesPurchased
Namespace Prefix:	incy_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the additional milestone payments to be made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the maximum number of independent programs encompassed under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementMaximumNumberOfIndependentPrograms
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of the milestone payment made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the number of additional preclinical discovery programs.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number Of Programs Terminated, Reversal Of Royalties

+ References

No definition available.

+ Details

Name:	incy_NumberOfProgramsTerminatedReversalOfRoyalties
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of programs in which the resulting products are co-funded for development.

+ References

No definition available.

+ Details

Name:	incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number Of Projects With Participation Rights

+ References

No definition available.

+ Details

Name:	incy_NumberOfProjectsWithParticipationRights
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.

+ References

No definition available.

+ Details

Name:	incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of net sales attributable to additional royalties.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfNetSalesPertainingToAdditionalRoyalties
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of profits (losses).

+ References

No definition available.

+ Details

Name:	incy_PercentageOfProfitsLosses
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of reverse royalties on sale of future products.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the purchase of common stock under Stock Purchase Agreement.

+ References

No definition available.

+ Details

Name:	incy_PurchaseOfCommonStockUnderStockPurchaseAgreement
Namespace Prefix:	incy_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

This element represents the aggregate cost of investments accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentQuotedMarketValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_MerusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: